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Abstract
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Objective—To determine the impact of treatment with oral naltrexone on healthcare costs in
patients with alcohol-related disorders.
Methods—Using data from the MarketScan Commercial Claims and Encounters Database for
2000–2004, we identified a Naltrexone Group (with an alcohol-related diagnosis and at least one
pharmacy claim for oral naltrexone) and two control groups. Alcohol Controls had an alcoholrelated diagnosis and were not prescribed an alcoholism treatment medication. Non-Alcohol
Controls had no alcohol-related diagnosis and no prescription for an alcoholism treatment
medication. The control groups were matched three to one to the naltrexone group on
demographic and other relevant measures. Healthcare expenditures were calculated for the sixmonth periods before and after the index naltrexone drug claim (or matched date for controls).
Univariate and multivariate analyses were used to compare the groups on key characteristics and
on healthcare costs.
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Results—Naltrexone patients (n=1,138; 62% male; mean age 45±11 years) had significantly
higher total health care expenditures in the pre-index period than either of the control groups. In
the post-index period, naltrexone patients had a significantly smaller increase than Alcohol
Controls in total alcohol-related expenditures. Total non–alcohol-related expenditures also
increased significantly less for the Naltrexone Group than for either control group. Multivariate
analyses showed that naltrexone treatment significantly reduced alcohol-related, non–alcoholrelated, and total healthcare costs relative to Alcohol Controls.
Conclusions—Although prior to treatment, patients with alcohol-related disorders had higher
healthcare costs, treatment with oral naltrexone was associated with reductions both in alcoholrelated and non–alcohol-related healthcare costs.
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INTRODUCTION
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Alcohol use disorders (AUDs, which include alcohol abuse and alcohol dependence) are
highly prevalent in the United States, with nearly 8.5% of the population meeting current
(i.e., past-year) criteria for these disorders (Grant et al., 2004). AUDs are of considerable
public health and economic significance, due to the high frequency of associated medical,
psychiatric, family, legal, and work-related problems (Caetano and Cunradi, 1997). The
annual cost of AUDs in the United States was estimated to be nearly $185 billion for 1998
(Harwood, 2000), which in view of rising healthcare costs, is likely to be a substantial
underestimate of current costs.
Despite the adverse effects of AUDs, the vast majority of individuals with these disorders
never receive treatment (Cohen et al., 2007, Mojtabai et al., 2002, Rabinowitz et al., 1999,
Regier et al., 1993, Wu et al., 2003). Recent efforts to improve both the efficacy and the
acceptability of alcohol treatment have included the identification and testing of medications
to treat alcohol dependence. This effort has resulted in the approval by the U.S. Food and
Drug Administration of two oral medications (naltrexone and acamprosate), as well as a
new, injectable, extended-release naltrexone formulation (Garbutt et al., 2005). These
medications are in addition to disulfiram, which was approved during the mid-20th century.
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A substantial literature shows that interventions to reduce heavy drinking or prevent relapse
in alcoholism result in reduced healthcare costs, even when the cost of the treatment is
accounted for (e.g., Holder and Blose, 1992, Holder, 1998, Parthasarathy et al., 2001,
Pettinati et al., 1999). Pettinati et al. (1999) examined the effects of different modalities of
alcohol treatment on this cost offset. Kranzler et al. (2008) used data from the 2000–2004
MarketScan® Commercial Claims and Encounters Database to identify patients with
alcohol-related claims who were prescribed oral naltrexone. Of 1,138 patients, 162 (14.2%)
were persistent in obtaining naltrexone, which was defined as having filled prescriptions for
≥80% of the 6-month treatment period. Non-persistence with naltrexone was associated with
a significantly greater use of costly healthcare services. That study did not, however,
compare healthcare utilization by naltrexone-treated patients with that of other patients.
Hence, the present study compared healthcare costs for patients with an alcohol-related
disorder who received naltrexone treatment with those of individuals with an alcohol-related
disorder who were not prescribed pharmacotherapy and with a group of non-alcoholic
individuals.

METHODS
NIH-PA Author Manuscript

The study used the MarketScan® Commercial Claims and Encounters (Commercial)
Database for healthcare services incurred during the five-year period January 1, 2000
through December 31, 2004. The healthcare business of the information company Thomson
Reuters (New York, NY) constructs the MarketScan databases from the paid medical and
prescription drug claims of individuals insured through its large self-insured employer and
health plan clients located throughout the United States. In constructing the databases,
information on healthcare claims from almost 100 payers, including self-ensured employers,
commercial insurance companies, Blue Cross and Blue Shield plans, and third-party
administrators, is standardized and de-identified so that the resulting databases can be used
to study real-world treatment patterns.
The resulting Commercial database included the healthcare claims of 12 million insured
individuals per year, on average, from 2000 through 2004. The claims come from all types
of healthcare providers that submit information for payment to health plans and other
payers, including hospitals, residential treatment facilities, physician offices, clinics, and
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retail and mail-order pharmacies. Each record in the database represents a unique healthcare
service for which payment was requested. Individual database records (i.e., claims) were
compiled at the patient level to study the healthcare utilization patterns of covered
individuals. In addition to claims, basic demographic and health plan enrollment information
is included in the database. Approximately 40% of health plans and other payers included in
the database do not cover or they carve out substance abuse treatment, to avoid including
patients with incomplete data, we limited the study sample to patients who had substance
abuse coverage through their health plans.
Sample Selection Criteria
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The Naltrexone Group had one or more claims for oral naltrexone between July 1, 2000 and
June 30, 2004, the earliest of which occurring during this period was set as the study index
date. Patients who were not continuously enrolled in a health plan for six months before and
six months after the index date were excluded since their claims histories during the study
period would be incomplete. Because the aim of the study was to compare healthcare
utilization and expenditures before and after the initiation of oral naltrexone therapy,
patients with claims for naltrexone (as well as disulfiram or acamprosate, which could
confound the analyses) in the three months pre-index were excluded from the analysis. .
Patients with earlier pre-index claims for these drugs were retained in the sample because a
three-month gap in therapy was deemed to reflect a new course of treatment. Because the
data were from the period preceding the availability of extended-release naltrexone for
clinical use, there were no claims for that medication. To focus the analysis on patients who
were receiving naltrexone to treat an alcohol use disorder, patients without one or more
alcohol-related diagnoses in the six months before or after the index date were excluded.
Alcohol-related diagnoses were defined broadly using the criteria of the International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and a list of
diagnoses from Harwood et al. (1998). The following alcohol-related conditions were
represented to ensure that all individuals with clinically significant effects of alcohol were
included: Alcoholic psychoses; alcohol dependence syndrome; nondependent abuse of
alcohol; alcoholic polyneuropathy; alcoholic cardiomyopathy; alcoholic gastritis; alcoholic
fatty liver; acute alcoholic hepatitis; alcoholic cirrhosis of the liver; alcoholic liver damage,
unspecified; fetal alcohol syndrome (in which case the mother was identified as the patient);
excessive blood level of alcohol; toxic effects of ethyl alcohol; and accidental poisoning by
alcohol.
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Two control groups were selected for the analysis: 1) Alcohol Controls were patients with
one or more claims for an alcohol-related diagnosis; no drug claims for naltrexone,
disulfiram or acamprosate; and six months of continuous enrollment prior to the index date
and following the index date. 2) Non-Alcohol Controls were patients with no claims for an
alcohol-related diagnosis; no drug claims for naltrexone, disulfiram or acamprosate; and six
months of continuous enrollment prior to the index date and following the index date.
Because these
All patients in the database meeting the control sample criteria were eligible to be matched
to the Naltrexone sample for analysis. To ensure an even distribution of demographic
characteristics that could influence healthcare utilization in all cohorts, thereby reducing
confounding, both the Alcohol Controls and the Non-Alcohol Controls were individually
matched 1:3 to patients in the Naltrexone Group on the basis of gender, age, geographic
region, relationship to primary insured, health plan type, and index quarter/year. Matches
were assigned randomly from among all patients in the database who met the control sample
criteria. The match ratio was chosen to enhance the capacity to detect potential cost
differences because, although costs are generally highly skewed, even a small cost
Alcohol Clin Exp Res. Author manuscript; available in PMC 2011 August 22.

Kranzler et al.

Page 4

difference between groups could be meaningful. Because matching more than 3 cases to
each control usually does not add power, a 1:3 match ratio was used (Mandrekar, 2004).
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Variables
Index Date—To determine the costs associated with naltrexone treatment, we chose an
index date, which was the date from which we started to calculate healthcare costs and
expenditures. For the Naltrexone Group, the index date was the date of the earliest
naltrexone claim, between July 1, 2000 and June 30, 2004. The inclusion criteria required a
three-month “clean period” before the earliest naltrexone claim; this prevented confounding
by the effects of recent pharmacotherapy for an alcohol-related diagnosis. Hence, the index
date represented the initiation of naltrexone therapy, following at least three months with no
evidence of alcohol-related pharmacotherapy (naltrexone, disulfiram, or acamprosate).
The index date for the control groups was randomly assigned such that the distribution of
index dates by year and quarter did not differ significantly from that of the naltrexone
cohort. The pre-index period was defined as the 6 months immediately preceding the index
date. The post-index period started on the index date and continued for 6 months.

NIH-PA Author Manuscript

Demographic and Clinical Measures—The following standard demographic variables
were available on insurance claims and included in the analysis: sex, age in years at index,
geographic region (Northeast, North Central, South, West), relationship of patient to primary
insured (Self/employee, Spouse, Child/other), Capitated Insurance (Yes, No), and Insurance
Plan Type (Basic, Comprehensive, EPO, HMO, Non-capitated POS, PPO, Capitated POS).
These measures were selected because of their potential impact on healthcare expenditures.
To assess co-occurring medical conditions present in the pre-index and the post-index
periods we used two claims-based comorbidity indices, the Charlson Comorbidity Index
(CCI) (D’Hoore et al., 1996) and the Chronic Disease Score (CDS) (Von Korff et al., 1992).
The CCI, one of the most widely used measures of the combined burden of disease or
conditions (Valderas et al., 2009) is based on ICD-9-CM diagnosis codes. The CDS is a
risk-adjustment measure based on age, gender, and history of dispensed drugs that predicts
hospitalization and can be used as an indicator of baseline comorbidity for control of
confounding (Putnam et al., 2002). Although for both measures, higher scores indicate a
greater burden of comorbidity, because they can yield slightly different results, both were
used to control for the impact that the treatment of comorbid conditions has on total
expenditures.

NIH-PA Author Manuscript

Alcohol-Related and Drug-Related Diagnoses—Patients were identified as having
an alcohol-related condition if they had at least one medical claim with one of the alcoholrelated ICD-9-CM diagnosis codes (Harwood et al., 1998). The diagnosis code could be
present on any diagnosis field (primary or secondary) and on any type of claim [inpatient,
emergency department (ED), outpatient]. Patients were identified as having a drug-related
condition if they had at least one medical claim for one of the drug-related ICD-9-CM
diagnosis codes (Harwood et al., 1998). Separate binary (yes/no) alcohol and drug diagnosis
variables were created for the six-month pre-index period and the six-month study period.
Medical Care Costs—We calculated total healthcare payments using the gross payment
field on inpatient, outpatient, and prescription claims. The gross payment represents the total
amount eligible for payment for a service, including both the health plan and patient (e.g.,
co-payment, deductible) portions. All costs were adjusted to December 2004 dollars using
the medical component of the Consumer Price Index (CPI). Separate figures were tallied for
the six-month pre-index period and the six-month post-index period. In addition to providing

Alcohol Clin Exp Res. Author manuscript; available in PMC 2011 August 22.

Kranzler et al.

Page 5

NIH-PA Author Manuscript

a sum of total expenditures, we reported expenditures associated with specific subsets of
claims. Subgroups examined included place or type of service [i.e., inpatient hospital, ED,
outpatient, and outpatient pharmacy]. We also divided expenditures into alcohol-related and
non-alcohol-related, on the basis of the primary diagnosis code listed on each claim.
Alcohol-related expenditures included inpatient, ED, and outpatient services claims where
the primary diagnosis was an alcohol-related code, and drug claims for naltrexone. We
considered only primary diagnoses in attributing costs as alcohol-related because of the
potential to over count services if the secondary diagnosis referred to a mitigating factor
rather than the reason for treatment. All other claims were considered non-alcohol related.
Medical Care Utilization—We examined medical care utilization rates by place or type
of service (i.e., inpatient hospitalizations, ED visits, outpatient visits, and outpatient
pharmacy prescriptions). For each place or type of service, we created a binary (yes/no)
variable denoting the presence of any service and a continuous variable to record the number
of relevant services. As with costs, utilization was examined overall and for alcohol-related
services as identified by diagnoses on the claims.

NIH-PA Author Manuscript

In addition, we identified patients with certain types of alcohol-related treatment, including
individual psychotherapy, group psychotherapy, outpatient detoxification and inpatient
detoxification. This information was obtained for both the six-month pre-index period and
the six-month post-index period. Procedure codes present on claims were used to identify
patients with these services. In addition, MarketScan place of service codes were used to
differentiate inpatient and outpatient detoxification.
Descriptive Analyses
Descriptive information included the demographic and clinical characteristics of the
Naltrexone Group and both control groups, as well as their utilization and expenditures in
the pre-index period and study period. Dependent variables also included utilization and cost
measures, as well as specific measures of alcohol-related medical complications. Utilization
included: (1) number of outpatient visits, (2) number of hospitalizations, (3) number of days
hospitalized, (4) number of ED visits, (5) number of prescriptions, and (6) sum of days
supplied across all prescriptions. Cost measures were calculated as paid claims after
discounts. Cost measures included: (1) total medical care expenditures, (2) outpatient
expenditures, (3) inpatient expenditures, (4) ED expenditures and (5) pharmaceutical
expenditures.
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Statistical testing was used to examine differences between the naltrexone and control
samples. T-tests were used to analyze normally distributed continuous variables, Wilcoxon
rank-sum tests to analyze non-normally distributed continuous variables, and chi-square
tests were used to analyze categorical variables. To account for within-subject correlation,
paired t-tests were used to test the difference between the pre-index and post-index period
expenditures.
Multivariate Analyses
Multivariate analyses were used to provide cost estimates that control for confounding
factors. The final specification of the multivariate models was driven, in part, by the results
of the descriptive analysis. Difference-in-difference (DID) regression analyses were used to
generate a more accurate estimate of the total expenditure impact of naltrexone treatment.
Each individual had two observations: one in the period before the index date and one in the
period after the index date. The generalized estimating equation (GEE) method was used to
account for correlation between repeated measures across individuals. Nonlinear
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specification of the cost equation was estimated to account for the non-normal distribution
of the error term (Liang and Zeger, 1986).
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The general specification of the DID regression was as follows:
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In this specification, Total $ refers to total health care expenditures in the pre-index and
post-index periods (measured separately for each patient). The letter f refers to the
assumption of a formal, empirical (i.e., exponential) relationship between health care
expenditures and the factors in parentheses. “T” indicates whether the outcome is measured
before or after treatment. “Alcohol Control” is a binary indicator denoting individuals with
an alcohol diagnosis who did not receive treatment. The variable labeled “T*Alcohol
Control” denotes the interaction between post-index expenditures and an alcohol diagnosis
without treatment. “Non-alcohol Control” is a binary indicator denoting individuals without
an alcohol diagnosis. The variable labeled “T*Non-alcohol Control” denotes the interaction
between post-index expenditures and no alcohol diagnosis. X refers to all other covariates.
In addition to the demographic and clinical characteristics included in Table 1, covariates
included health plan type (indemnity, preferred provider organization, health maintenance
organization); the primary insured’s employee type (salary or hourly) and status (actively
employed or retired); the median income in the 3-digit zip code area corresponding to the
patient’s residence; and binary indicators for a pre-index substance-abuse diagnosis, preindex psychotherapy, and post-index psychotherapy.
Ultimately, DID regression analyses, using the equation below, provided an estimate of the
total impact on expenditures of naltrexone treatment.

This DID design compared the difference in healthcare expenditures between the six-month
pre-index period and the six-month study period, for the Naltrexone Group to the same
difference in the other patient groups. The DID analysis also allowed us to control for
differences in mean baseline expenditures that could be due to health conditions that we did
not measure.

RESULTS
NIH-PA Author Manuscript

Univariate Analyses
There were 1,138 patients in the Naltrexone Group. Following matching, there were 3,411
Alcohol Controls and 3,410 Non-Alcohol Controls. Because appropriate matches could not
be found for a few naltrexone patients, both control groups were just short of a complete 1:3
match.
The demographic characteristics of the three groups are presented in Table 1. Sixty-two
percent of the patients were male and the mean age was 45 years. The sample was
distributed across the four geographic regions as follows: 24% resided in the Northeast, 36%
in the North Central region, 26% in the South and 14% in the West. Sixty percent were
employees, 34% spouses of insured employees, and 6% were children or other dependents,
nearly all of whom were 18 years of age or older. Most (72%) had non-capitated insurance
coverage. Several different insurance plan types were represented in the sample, the most
common of which was the preferred provider organization (PPO), with one-third of patients
Alcohol Clin Exp Res. Author manuscript; available in PMC 2011 August 22.
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having this plan type. Some patients had index dates in each year from 2000 through 2004,
but most of the sample had index dates in 2001, 2002 or 2003. As would be expected given
the matching, the control groups did not differ significantly from the Naltrexone Group on
any demographic variable.
As shown in Table 1, although all groups had low comorbidity scores during the pre-index
period, the Naltrexone Group had more comorbid medical conditions than either control
group, as evidenced by significantly higher CCI and CDS scores. Comorbidity scores were
also generally low in all three samples during the post-index period. However, during this
time, the CCI score of the Naltrexone Group was significantly lower than that of the Alcohol
Controls, but significantly higher than that of the Non-Alcohol Controls. Similar trends were
evident for the CDS scores. More naltrexone patients than controls had drug-related claims
in both the pre- and post-index periods (data not shown).
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The corresponding expenditure results were similar, as shown in Figure 1. Mean pre-index
alcohol-related expenditures were significantly higher for the Naltrexone Group than the
Alcohol Controls ($1,352 vs. $68, p<0.001). (Expenditures related to naltrexone, disulfiram
or acamprosate during this period amounted to only $13 of total expenditures for the
Naltrexone Group; data not shown.) Naltrexone patients also had higher mean pre-index
non-alcohol-related ($3,478 vs. $2,435, p<0.001) and total (alcohol-related plus nonalcohol-related) expenditures than either the Alcohol Controls or the Non-Alcohol controls
($4,829 vs. $2,503, p<0.001 and vs. $1,404, p<0.001, respectively). In the post-index period,
mean alcohol-related expenditures were higher in the Naltrexone Group than in the Alcohol
Controls ($1,415 vs. $882, p<0.001). (These expenditures included $268 for naltrexone,
disulfiram or acamprosate prescriptions; data not shown.) Non-alcohol-related expenditures
did not differ significantly between these two groups ($4,005 vs. $3,694, p=0.16). Mean
total expenditures for the Naltrexone Group were higher than for both control groups
($5,420 vs. $4,576 for Alcohol Controls and $1,496 for Non-Alcohol Controls, p<0.001).
Comparing the difference between pre-index period and post-index period expenditures,
however, indicated that the alcohol-related expenditures for the naltrexone group were only
$63 dollars higher in the post-index period than in the pre-index period, while the difference
for the controls with an alcohol-related diagnosis was an increase of $814 (p<0.0001). The
smaller pre-post difference for the Naltrexone group is especially notable given that these
patients incurred post-index expenditures for naltrexone prescriptions, while the Alcohol
Controls had no such expenditures in the post-index period. The trends for non-alcoholrelated and total expenditures were similar to those for alcohol-related expenditures.

NIH-PA Author Manuscript

Specific types of service utilization are shown in Table 2. As can be seen there, a small
proportion (<5%) of patients in the Naltrexone group had claims for oral naltrexone or
disulfiram/acamprosate in the pre-index period, but more than three months prior to the
index date. Given the requirement that controls be free of these medications, no such use
was seen among the Alcohol Controls. One-half of the Naltrexone Group had an alcoholrelated physician office visit in the pre-period, compared to only 5% of the Alcohol Controls
(p<0.0001). The corresponding rates for outpatient alcohol-related psychotherapy visits were
17% and 3% (p<0.0001). A larger proportion of the Naltrexone Group also utilized nonalcohol-related services in the pre-index period than either of the control groups, with nearly
all comparisons being highly statistically significant.
In the post-index period, however, only the rate of alcohol-related ED visits differed
significantly between these group, with the Alcohol Controls being more likely to
experience an alcohol-related ED visit [15% compared to only 9% of naltrexone patients
(p=0.015)]. In the post-index period, Alcohol Controls also were more likely than naltrexone
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patients to have non-alcohol-related inpatient admissions and ED visits (p=0.036 and
p=0.031, respectively). The percentage of patients with outpatient physician visits or
prescription drug use was higher in the Naltrexone Group than the Alcohol Controls, though
not significantly so (p=0.53 and p=0.052, respectively). In the post-index period, NonAlcohol Controls used significantly fewer non-alcohol-related services than did naltrexone
patients (all categories of services showing highly significant differences).
Multivariate Analyses
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After adjusting for baseline differences, we observed that the trend over time in expenditures
was significantly higher for Alcohol Controls than for the Naltrexone Group. The average
medical care expenditures for the Naltrexone Group before and after treatment relative to the
Alcohol Controls with the same characteristics were predicted from the model using
simulations. The expenditure trend estimates are noted in Table 3. They suggest that average
alcohol-related, non-alcohol-related, and total expenditures for the Naltrexone Group
increased over time by about $58, $654, and $732, respectively, per patient, while average
expenditures for Alcohol Controls increased by about $815, $1,590, and $2,559,
respectively. Thus, the use of naltrexone resulted in an overall savings in total healthcare
expenditures of about $1,827 per patient (i.e., $732 – $2,559 = −$1,827; p-value < 0.0001).
Results using alternate modeling strategies, such as ordinary least squares regression, were
similar, though the magnitude of the savings estimate in total healthcare expenditures
associated with naltrexone use was somewhat lower, ranging from $1,442 to $1,483.

DISCUSSION
Univariate comparisons indicated that the three groups were matched successfully on
demographic measures. Although overall the study groups had a low level of comorbidity,
the descriptive results identified some differences between the naltrexone and control groups
on these measures, which were controlled for in the multivariate analysis.
Naltrexone patients had higher mean total healthcare expenditures than patients without an
alcohol-related disorder, in part due to expenditures for naltrexone and alcohol-related
services. A similar comparison showed significantly higher mean non-alcohol-related
expenditures, consistent with prior findings that the healthcare impact of alcohol-related
disorders extends beyond alcohol-related services (Parthasarathy et al., 2001).
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Naltrexone use was associated with a reduction in both alcohol-related and non-alcoholrelated healthcare expenditures among patients with alcohol-related diagnoses. The savings
occurred over a relatively short timeframe – six months after the initiation of naltrexone
therapy – and were significant despite the fact that naltrexone patients incurred costs for
naltrexone pharmacotherapy that the controls did not incur.
Following an initial increase in costs, which is thought to reflect a pent-up need for
healthcare that is finally being met in the course of early recovery (Holder and Blose, 1992),
there was a decrease in the use of more costly, intensive treatment services, such as ED
visits and inpatient stays, which translated overall into a smaller increase in costs than was
seen among the Alcohol Controls. The detection of a differential economic benefit with
naltrexone within only six months of its initiation may reflect a benefit of adding the
medication to alcoholism treatment not only in terms of cost but also in time.
Figure 1 shows that the greater increase in healthcare costs over time in the Alcohol
Controls were due to the lower alcohol-related and non-alcohol related costs in this group
than in the Naltrexone Group during the pre-period. During the post-period, alcohol-related
and non-alcohol-related costs were comparable in the two groups. We would speculate that
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this reflects a stabilization of the Naltrexone Group’s course. In contrast, in the absence of
naltrexone, the Alcohol Controls may have shown the cumulative adverse medical effects of
continued heavy drinking, which were reflected in both alcohol-related and alcohol-nonrelated costs. Correlation of the change in healthcare costs with data on drinking behavior,
which were not available for use in the present study, would make it possible to evaluate this
hypothesis and should be the focus of subsequent studies.
The differences in healthcare utilization between the Naltrexone Group and the Alcohol
Controls are also reflected in the kinds of alcohol-related services that were utilized and how
these changed over time. In the pre-period, the Naltrexone Group made significantly more
alcohol-related outpatient medical and psychotherapy visits and ED visits, consistent with
the adverse consequences of heavy drinking. Interventions, which included the prescribing
of naltrexone, appeared to stabilize these individuals’ course. In contrast, utilization of these
services by the Alcohol Control Group, which was low during the pre-period, increased
dramatically during the post-period, consistent with cumulative adverse consequences of
heavy drinking and efforts by their healthcare practitioners to treat their alcohol-related
disorders.
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In short, the Naltrexone Group and the Alcohol Controls, despite being matched on a variety
of demographic and clinical variables during the pre-period, differed on a variety of
measures of healthcare utilization. It appears that the Naltrexone Group was prescribed this
opioid antagonist medication in the context of a variety of alcohol-related healthcare
services. Using utilization data, it is not possible to partial out the impact of the naltrexone
per se and an alternate explanation for the observed trajectories is that factors other than
naltrexone (i.e., both treatment-related and possibly reflecting regression to the mean) were
responsible for the differential change in healthcare utilization between the Naltrexone
Group and the Alcohol Controls.
This study has a number of strengths, including the use of two comparison groups, one of
which was diagnosed with an alcohol-related disorder and the other without such a
diagnosis, which made it possible to evaluate temporal trends that might otherwise confound
the interpretation of the findings (Holder and Blose, 1992). The use of GEE accounted for
the autocorrelation that occurs among individuals with repeated measurements (Liang and
Zeger, 1986). Finally, the detailed healthcare utilization information available made it
possible to examine different modalities of treatment received, both alcohol-related and nonalcohol-related, resulting in a more detailed and revealing analysis of the impact of
naltrexone treatment on healthcare utilization.
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These results should be interpreted in light of the usual limitations of analyses using
administrative data. Because this study used only information available on insurance claims,
it was necessary to include patients with a variety of alcohol-related disorders, which served
as a proxy measure of an alcohol use disorder and it was not possible to stratify patients by
the level of severity of their alcohol-related disorder. Because data for individuals with an
oral naltrexone claim who did not meet all study inclusion and exclusion criteria were not
extracted from the database, it was not possible to compare the characteristics of excluded
oral naltrexone patients to the study sample. Psychiatric comorbidity may have differed by
cohort, but was not assessed. Nor was it possible to ascertain patients’ motivation to seek
alcohol-related services. There was no way to verify that patients with an alcohol-related
diagnosis did, in fact, have such a diagnosis and some patients in the control group without
an alcohol-related diagnosis could have had an alcohol-related disorder that was not coded
in their insurance claims. Naltrexone is also approved to treat opioid dependence, so it is
possible that some individuals were prescribed naltrexone to treat that disorder, rather than
an alcohol-related disorder. Because naltrexone is prescribed for opioid dependence
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infrequently, it is unlikely that this is an important consideration in the interpretation of the
data presented here. Some patients in the Naltrexone Group had evidence of pre-index use of
naltrexone, disulfiram or acamprosate. Although the small number of such patients suggests
that their impact on study results was minimal, this was not specifically assessed. In
addition, because only services billed to insurers could be quantified, we were unable to
assess modalities such as participation in Alcoholics Anonymous, so it is not known whether
their utilization differed between the naltrexone and control groups.
Despite these limitations, the findings of this analysis are notable. They suggest that there is
a cost savings to payers of making treatment with naltrexone available to their enrollees. The
pre-to-post decrease in non-alcohol-related healthcare utilization seen among the naltrexone
patients but not among the Alcohol Controls indicates that naltrexone treatment may also
decrease the overall burden on the healthcare system.
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It may be feasible to derive more benefit from naltrexone treatment than is evident from
these results. Rates of adherence to treatment with oral naltrexone have been shown to be
poor, with most patients unable to complete a clinical course of treatment (Harris et al.,
2004, Hermos et al., 2004, Kranzler et al., 2008). A prior analysis of data from the
Naltrexone Group included in the present study showed that of patients prescribed oral
naltrexone, nearly 86% did not fill their prescriptions for at least 80% of the days over a sixmonth period and approximately 50% failed to refill even one prescription (Kranzler et al.,
2008). Patients who persisted in refilling at least 80% of the prescriptions during the sixmonth period showed significantly lower rates of use of intensive medical services
compared to patients who did not meet this persistence criterion, including fewer ED
contacts, hospital admissions and inpatient alcohol detoxifications. This finding has
relevance for the question of whether the different trajectories of the Naltrexone Group and
the Alcohol Controls were due to treatment with the medication. Although it is possible that
naltrexone was prescribed to individuals who were perceived to have a better prognosis, the
low persistence rate for naltrexone argues against this interpretation. Further, the higher
alcohol-related healthcare costs in the Naltrexone Group than the Alcohol Controls during
the pre-period is inconsistent with the notion that the Naltrexone Group was more stable
than the Alcohol Controls.
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These observations underscore the potential importance of initiating medication treatment
for alcohol dependence and of optimizing medication adherence. Such efforts can include
behavioral approaches (e.g., daily observed pill administration) that have been shown to
enhance adherence (Cramer et al., 2003, O’Farrell et al., 1995, Pettinati et al., 2000, Starosta
et al., 2006) or long-acting preparations such as extended-release injectable naltrexone
(Garbutt et al., 2005).
Finally, because of the relatively short duration of monitoring, the observed effects on
healthcare utilization may be an underestimate of the actual impact. Additional studies using
a longer duration of monitoring appear warranted to estimate more accurately the cost offset
resulting from the use of naltrexone to treat alcoholism. Particular attention is also required
to differentiate the effects of the medication from co-occurring interventions that follow
from the recognition by healthcare practitioners that an individual’s drinking is problematic.
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Figure 1.

Mean Alcohol and Non-Alcohol Expenditures during the 6-Month Pre-Index and Post-Index
Periods
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Table 3

Change in Expenditures Pre- and Post-Index After Controlling for Confounders in the Multivariate Analysis
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ECM Difference in Difference Model: Gamma with Log Link
Expenditure Type

Naltrexone Group vs. Alcohol Controls

Naltrexone Group vs. Non-Alcohol Controls

Alcohol-Related

−$758

$58

Non-Alcohol-Related

−$937
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−$1,827

$586

Total
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